RTW Investments’s Cytek Biosciences CTKB Stock Holding History

RTW Investments’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-916,838	Closed	-$9.84M	–	90
2022 Q2	$9.84M	Buy	+916,838	New	+$9.13M	0.25%	58

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RTW Investments's CTKB Position: Q3 2022 in Review

RTW Investments sold out of Cytek Biosciences (CTKB) in Q3 2022, closing a stake of 916,838 shares — an estimated $9.84M sold.

RTW Investments first reported a position in CTKB in Q2 2022 and held it in 1 quarter. The position peaked at $9.84M in Q2 2022. 88 funds tracked by Wall St. Rank hold CTKB as of Q3 2022.

RTW Investments reported no remaining Cytek Biosciences position as of Q3 2022 after selling out during the quarter.
RTW Investments sold 916,838 Cytek Biosciences shares in Q3 2022, an estimated $9.84M.
RTW Investments first reported a position in Cytek Biosciences in Q2 2022 and held it in 1 quarter.
RTW Investments's Cytek Biosciences position peaked at $9.84M in Q2 2022.
88 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2022.

Based on RTW Investments's 13F filing for Q3 2022, filed 14 Nov 2022.